[ad_1]
Takeda, a global biopharmaceutical company, and Biological E. Limited (BE) on Tuesday announced a strategic partnership to accelerate access to Qdenga (quadrivalent dengue vaccine). [Live, Attenuated]) (TAK-003), multi-dose vials (MDV).
A press release from Takeda said these doses will eventually be available for purchase by governments of endemic countries no later than 2030 to support national immunization programs.
Under the partnership, BE will ramp up to manufacturing capacity of up to 50 million doses per year, accelerating Takeda’s efforts to manufacture 100 million doses per year within the decade.
The partnership will build on existing manufacturing capacity for the vaccine at Takeda’s facility in Singen, Germany, and Takeda’s long-term partnership with IDT Biologika GmbH.
MDVs offer economic and logistical advantages to National Immunization Programs by minimizing packaging and storage expenses, while reducing medical and environmental waste, he added.
“We are proud to announce a strategic manufacturing partnership with Biological E. Limited, which has deep experience in vaccine manufacturing and long-standing support of public health programs around the world.
“Together, we will help combat dengue on a global scale by significantly increasing Qdenga’s multidose vial manufacturing capacity to drive sustainable access to the vaccine in more endemic countries,” said Gary Dubin, president of the Vaccines Global Business Unit at Takeda. saying.
“We are proud to collaborate with Takeda in the production of their innovative quadrivalent dengue vaccine, Qdenga, in multi-dose vials,” said Mahima Datla, CEO of Biological E. Limited.
Qdenga is currently available for children and adults in the private market in countries in Europe, Indonesia and Thailand, and in private and some public programs in Argentina and Brazil. TAK-003 is not approved for use in India.